EXCEL Clinical Trial

Coronary Artery Disease Clinical Trial

— EXCEL  

Official title:

Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01205776
• Other study ID #: 10-389
• Status: Completed
• Phase: N/A
• Start date: September 29, 2010
• Est. completion date: June 28, 2019

Study information

• Verified date: March 2020
• Source: Abbott Medical Devices
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO [for use outside the United States [OUS] only]) in subjects with unprotected left main coronary artery disease by comparing to coronary artery bypass graft surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1905
• Est. completion date: June 28, 2019
• Est. primary completion date: May 3, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Inclusion criteria for RCT:

• Unprotected left main coronary artery (ULMCA) disease with angiographic diameter stenosis (DS) =70% requiring revascularization, or

• ULMCA disease with agniographic DS >=50% but < 70% requiring revascularization, with one or more of the following present:

• Non-invasive evidence of ischemia referable to a hemodynamically significant left main lesion (large area of ischemia in both the LAD and LCX territories, or in either the LAD or LCX territory in the absence of other obstructive coronary artery disease to explain the LAD or LCX defect), or stress-induced hypotension or stress-induced fall in LVEF, or stress-induced transient ischemic dilatation of the left ventricle or stress-induced thallium/technetiumlung uptake, and/or

• IVUS minimum lumen area (MLA) <= 6.0mm2, and/or

• Fractional Flow Reserve (FFR) <=0.80

• Left Main Equivalent Disease

• Clinical and anatomic eligibility for both PCI and CABG

• Silent ischemia, stable angina, unstable angina or recent MI

• Ability to sign informed consent and comply with all study procedures including follow-up for at least three years

Exclusion Criteria:

• Clinical exclusion criteria:

• Prior PCI of the left main trunk at any time prior to randomization

• Prior PCI of any other coronary artery lesions within one year prior to randomization

• Prior CABG at any time prior to randomization

• Need for any concomitant cardiac surgery other than CABG, or intent that if the subject randomizes to surgery, any cardiac surgical procedure other than isolated CABG will be performed

• CK-MB greater than the local laboratory upper limit of normal or recent MI with CK-MB still elevated

• Subjects unable to tolerate, obtain or comply with dual antiplatelet therapy for at least one year

• Subjects requiring or who may require additional surgery within one year

• The presence of any clinical condition(s) which leads the participating interventional cardiologist to believe that clinical equipoise is not present

• The presence of any clinical condition(s) which leads the participating cardiac surgeon to believe that clinical equipoise is not present

• Pregnancy or intention to become pregnant

• Non cardiac co-morbidities with life expectancy less than 3 years

• Other investigational drug or device studies that have not reached their primary endpoint

• Vulnerable population who in the judgment of the investigator is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include: Individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention

Angiographic exclusion criteria:

• Left main diameter stenosis <50%

• SYNTAX score =33

• Left main reference vessel diameter <2.25 mm or >4.25 mm

• The presence of specific coronary lesion characteristics or other cardiac condition(s) which leads the participating interventional cardiologist to believe that clinical equipoise is not present

• The presence of specific coronary lesion characteristics or other cardiac condition(s) which leads the participating cardiac surgeon to believe that clinical equipoise is not present

Related Conditions & MeSH terms

• Chronic Coronary Occlusion
• Coronary Artery Disease
• Coronary Artery Stenosis
• Coronary Disease
• Coronary Occlusion
• Coronary Restenosis
• Coronary Stenosis
• Ischemia
• Myocardial Ischemia
• Stent Thrombosis
• Thrombosis
• Unprotected Left Main Coronary Artery Disease
• Vascular Disease
• Vascular Diseases

Intervention

Device:
• Percutaneous Coronary Intervention
Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS

Procedure:
• CABG
Those patients receiving CABG

Locations

Country	Name	City	State
United States	Abbott Vascular	Santa Clara	California

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	5 years
Secondary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	In-hospital (= 7 days of index-procedure)
Secondary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	30 days
Secondary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 6 months
Secondary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 1 year
Secondary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 2 years
Secondary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 3 years
Secondary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 4 years
Secondary	Number of Participants With All-cause Death, Protocol Defined MI or Protocol Defined Stroke	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 5 years
Secondary	Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	In-hospital (= 7 days of index-procedure)
Secondary	Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 30 days
Secondary	Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 6 months
Secondary	Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 1 year
Secondary	Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia	All deaths includes Cardiac death, Vascular death and Non-cardiovascular death.; Myocardial Infarction (MI): Q wave MI: Development of new, pathological Q wave on the ECG.; Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).	0 to 2 years
Secondary	Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia	Death: Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).; Non-cardiac death is defined as a death not due to cardiac causes (as defined above).; Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.	0 to 3 years
Secondary	Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia	Death: Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).; Non-cardiac death is defined as a death not due to cardiac causes (as defined above).; Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.	0 to 4 years
Secondary	Number of Participants With Death, Protocol Defined MI, Protocol Defined Stroke or Unplanned Revascularization for Ischemia	Death: Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).; Non-cardiac death is defined as a death not due to cardiac causes (as defined above).; Myocardial Infarction (MI) -Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.; Unplanned revascularization for ischemia: Any repeat revascularization of either a target vessel or non-target vessel with any of the above criteria for ischemia met.	0 to 5 years
Secondary	Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.; • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	In-hospital (= 7 days of index-procedure)
Secondary	Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.; • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	0 to 30 days
Secondary	Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.; • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	0 to 6 months
Secondary	Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.; • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	0 to 1 year
Secondary	Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.; • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	0 to 2 years
Secondary	Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.; • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	0 to 3 years
Secondary	Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.; • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	0 to 4 years
Secondary	Number of Participants With All-cause Mortality (Cardiac Death and Non-cardiac Death)	All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.; • Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; • Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; • Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	0 to 5 years
Secondary	Number of Participants With Protocol Defined MI	Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	In-hospital (= 7 days of post index procedure)
Secondary	Number of Participants With Protocol Defined MI	Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	0 to 30 days
Secondary	Number of Participants With Protocol Defined MI	Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	0 to 6 months
Secondary	Number of Participants With Protocol Defined MI	Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	0 to 1 year
Secondary	Number of Participants With Protocol Defined MI	Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	0 to 2 years
Secondary	Number of Participants With Protocol Defined MI	Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	0 to 3 years
Secondary	Number of Participants With Protocol Defined MI	Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	0 to 4 years
Secondary	Number of Participants With Protocol Defined MI	Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	0 to 5 years
Secondary	Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)	Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).; Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.; Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.; All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.	In-hospital (= 7 days of index-procedure)
Secondary	Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)	Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).; Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.; Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.; All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.	0 to 30 days
Secondary	Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)	Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).; Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.; Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.; All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.	0 to 6 months
Secondary	Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)	Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).; Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.; Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.; All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.	0 to 1 year
Secondary	Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)	Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).; Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.; Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.; All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.	0 to 2 years
Secondary	Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)	Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).; Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.; Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.; All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.	0 to 3 years
Secondary	Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)	Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).; Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.; Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.; All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.	0 to 4 years
Secondary	Number of Participants With All Stroke (Ischemic Stroke, and Hemorrhagic Stroke)	Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).; Ischemic (Non-hemorrhagic): A stroke caused by an arterial obstruction due to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology.; Hemorrhagic: A stroke due to a hemorrhage in the brain as documented by neuroimaging or autopsy. This category will include strokes due to primary intracerebral hemorrhage (intraparenchymal or intraventricular), ischemic strokes with hemorrhagic transformation (i.e., no evidence of hemorrhage on an initial imaging study but appearance on a subsequent scan), subdural hematoma,* and primary subarachnoid hemorrhage.; All subdural hematomas that develop during the clinical trial should be recorded and classified as either traumatic versus nontraumatic.	0 to 5 years
Secondary	Number of Participants With Disability Following Stroke Event	In case of an event of stroke disability at 90-days±2 weeks will be an overall measurement of severity of stroke as assessed by modified Rankin Scale (mRS) scale.; Stroke disability will be classified using an adaptation of the modified Rankin Scale as follows, the assessment of which will be based on the Modified Rankin Disability Questionnaire.; Scale 0; No stroke symptoms at all. (May have other complaints) Scale 1; No significant disability; symptoms present but no physical or other limitations.; Scale 2; Slight disability; limitations in participation in usual social roles, but independent for activities of daily living (ADL) Scale 3; Some need for assistance but able to walk without assistance Scale 4; Moderately severe disability; need for assistance with some basic ADL, but not requiring constant care Scale 5; Severe disability; requiring constant nursing care and attention.	90 days ± 2 weeks
Secondary	Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; or; Ischemic ECG changes at rest in a distribution consistent with the target vessel; or; Typical ischemic symptoms referable to the target lesion; or; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; or; Fractional Flow Reserve (FFR) of the target lesion = 0.80	In-hospital (= 7 days of index-procedure)
Secondary	Number of Participants With Ischemia Driven Revascularizations	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; or; Ischemic ECG changes at rest in a distribution consistent with the target vessel; or; Typical ischemic symptoms referable to the target lesion; or; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; or; Fractional Flow Reserve (FFR) of the target lesion = 0.80	0 to 30 days
Secondary	Number of Participants With Ischemia Driven Revascularizations	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; or; Ischemic ECG changes at rest in a distribution consistent with the target vessel; or; Typical ischemic symptoms referable to the target lesion; or; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; or; Fractional Flow Reserve (FFR) of the target lesion = 0.80	0 to 6 months
Secondary	Number of Participants With Ischemia Driven Revascularizations	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; or; Ischemic ECG changes at rest in a distribution consistent with the target vessel; or; Typical ischemic symptoms referable to the target lesion; or; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; or; Fractional Flow Reserve (FFR) of the target lesion = 0.80	0 to 1 year
Secondary	Number of Participants With Ischemia Driven Revascularizations	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; or; Ischemic ECG changes at rest in a distribution consistent with the target vessel; or; Typical ischemic symptoms referable to the target lesion; or; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; or; Fractional Flow Reserve (FFR) of the target lesion = 0.80	0 to 2 years
Secondary	Number of Participants With Ischemia Driven Revascularizations	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; or; Ischemic ECG changes at rest in a distribution consistent with the target vessel; or; Typical ischemic symptoms referable to the target lesion; or; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; or; Fractional Flow Reserve (FFR) of the target lesion = 0.80	0 to 3 years
Secondary	Number of Participants With Ischemia Driven Revascularizations	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; or; Ischemic ECG changes at rest in a distribution consistent with the target vessel; or; Typical ischemic symptoms referable to the target lesion; or; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; or; Fractional Flow Reserve (FFR) of the target lesion = 0.80	0 to 4 years
Secondary	Number of Participants With Ischemia Driven Revascularizations	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; or; Ischemic ECG changes at rest in a distribution consistent with the target vessel; or; Typical ischemic symptoms referable to the target lesion; or; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; or; Fractional Flow Reserve (FFR) of the target lesion = 0.80	0 to 5 years
Secondary	Number of Participants With All Revascularizations (Ischemia-driven or Non Ischemia-driven)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; Ischemic ECG changes at rest in a distribution consistent with the target vessel; Typical ischemic symptoms referable to the target lesion; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; FFR of the target lesion = 0.80; A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis = 50% by QCA with any of the above criteria for ischemia met.	In-hospital (= 7 days of index-procedure)
Secondary	Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; Ischemic ECG changes at rest in a distribution consistent with the target vessel; Typical ischemic symptoms referable to the target lesion; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; FFR of the target lesion = 0.80; A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis = 50% by QCA with any of the above criteria for ischemia met.	0 to 30 days
Secondary	Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; Ischemic ECG changes at rest in a distribution consistent with the target vessel; Typical ischemic symptoms referable to the target lesion; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; FFR of the target lesion = 0.80; A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis = 50% by QCA with any of the above criteria for ischemia met.	0 to 6 months
Secondary	Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; Ischemic ECG changes at rest in a distribution consistent with the target vessel; Typical ischemic symptoms referable to the target lesion; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; FFR of the target lesion = 0.80; A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis = 50% by QCA with any of the above criteria for ischemia met.	0 to 1 year
Secondary	Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; Ischemic ECG changes at rest in a distribution consistent with the target vessel; Typical ischemic symptoms referable to the target lesion; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; FFR of the target lesion = 0.80; A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis = 50% by QCA with any of the above criteria for ischemia met.	0 to 2 years
Secondary	Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; Ischemic ECG changes at rest in a distribution consistent with the target vessel; Typical ischemic symptoms referable to the target lesion; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; FFR of the target lesion = 0.80; A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis = 50% by QCA with any of the above criteria for ischemia met.	0 to 3 years
Secondary	Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; Ischemic ECG changes at rest in a distribution consistent with the target vessel; Typical ischemic symptoms referable to the target lesion; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; FFR of the target lesion = 0.80; A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis = 50% by QCA with any of the above criteria for ischemia met.	0 to 4 years
Secondary	Number of Participants With All Revascularizations (Ischemia Driven and Not Ischemia Driven)	A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is = 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met: A positive functional study corresponding to the area served by the target lesion; Ischemic ECG changes at rest in a distribution consistent with the target vessel; Typical ischemic symptoms referable to the target lesion; IVUS of the target lesion with a minimal lumen area (MLA) of = 4 mm^2 for non left main lesions or = 6 mm^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the; plaque burden must also be = 60%; FFR of the target lesion = 0.80; A non target vessel revascularization will be considered ischemia-driven if any lesion the non target vessel has a diameter stenosis = 50% by QCA with any of the above criteria for ischemia met.	0 to 5 years
Secondary	Percentage of Participants With Major Adverse Events (MAE)	Composite of death, myocardial infarction, stroke, transfusion of = 2 units of blood, major arrhythmia, unplanned coronary revascularization for ischemia, any unplanned surgery or radiologic procedure, renal failure, sternal wound dehiscence, infection requiring antibiotics for treatment, intubation for > 48 hours, or post-pericardiotomy syndrome.	In-hospital
Secondary	Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable	Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.; Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive thrombus; Occlusive thrombus.; Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.; Probable stent thrombosis may occur after intracoronary stenting due to: Unexplained death within first 30 days; Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause.	Early (0-30 days)
Secondary	Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable	Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.; Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive thrombus; Occlusive thrombus.; Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.; Probable stent thrombosis may occur after intracoronary stenting due to: Unexplained death within first 30 days; Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause.	Acute (<= 24 hours)
Secondary	Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable	Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.; Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive thrombus; Occlusive thrombus.; Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.; Probable stent thrombosis may occur after intracoronary stenting due to: Unexplained death within first 30 days; Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause.	Subacute (1-30 days)
Secondary	Number of Participants With Stent Thrombosis (ARC Definition) Definite/Probable	Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.; Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive thrombus; Occlusive thrombus.; Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.; Probable stent thrombosis may occur after intracoronary stenting due to: Unexplained death within first 30 days; Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause.	Late (>30 days - 1 year)
Secondary	Number of Participants With Stent Thrombosis (ARC Definition) Definite/ Probable	Definite stent thrombosis occurred by either angiographic/pathologic confirmation of stent thrombosis.; Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive thrombus; Occlusive thrombus.; Pathological confirmation: Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy.; Probable stent thrombosis may occur after intracoronary stenting due to: Unexplained death within first 30 days; Irrespective of the time after the index procedure,any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause.	Very late (>1 year)
Secondary	Number of Participants With Graft Stenosis or Occlusion	Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	In-hospital (= 7 days of index-procedure)
Secondary	Number of Participants With Graft Stenosis or Occlusion	Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	0 to 30 days
Secondary	Number of Participants With Graft Stenosis or Occlusion	Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	0 to 6 months
Secondary	Number of Participants With Graft Stenosis or Occlusion	Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	0 to 1 year
Secondary	Number of Participants With Graft Stenosis or Occlusion	Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	0 to 2 years
Secondary	Number of Participants With Graft Stenosis or Occlusion	Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	0 to 3 years
Secondary	Number of Participants With Graft Stenosis or Occlusion	Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	0 to 4 years
Secondary	Number of Participants With Graft Stenosis or Occlusion	Graft stenosis or occlusion is defined as Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	0 to 5 years
Secondary	Number of Participants With Requirement for Blood Product Transfusion	All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows: ? Hemoglobin = [baseline Hgb - post-transfusion Hgb] + [number of transfused units]; ? Hematocrit = [baseline Hct - post-transfusion Hct] + [number of transfused units X 3].	30 days
Secondary	Number of Participants With Requirement for Blood Product Transfusion	All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows: ? Hemoglobin = [baseline Hgb - post-transfusion Hgb] + [number of transfused units]; ? Hematocrit = [baseline Hct - post-transfusion Hct] + [number of transfused units X 3].	3 years
Secondary	Number of Participants With Requirement for Blood Product Transfusion	All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows: ? Hemoglobin = [baseline Hgb - post-transfusion Hgb] + [number of transfused units]; ? Hematocrit = [baseline Hct - post-transfusion Hct] + [number of transfused units X 3].	4 years
Secondary	Number of Participants With Requirement for Blood Product Transfusion	All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in hemoglobin or hematocrit if there has been an intervening transfusion between two blood measurements is calculated as follows: ? Hemoglobin = [baseline Hgb - post-transfusion Hgb] + [number of transfused units]; ? Hematocrit = [baseline Hct - post-transfusion Hct] + [number of transfused units X 3].	5 years
Secondary	Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding	Bleeding will be classified by the TIMI hemorrhage classification; Severity: Major: Intracranial hemorrhage; A =5 g/dL decrease in the hemoglobin concentration; A =15% absolute decrease in the hematocrit; Minor: Observed blood loss: A = 3 g/dL decrease in the hemoglobin concentration; A = 10% absolute decrease in the hematocrit; No observed blood loss: A = 4 g/dL decrease in the hemoglobin concentration; A = 12% absolute decrease in the hematocrit; Minimal: • Any clinically overt sign of hemorrhage (including imaging) that is associated with a < 3 g/dL decrease in hemoglobin concentration or < 9% decrease in the hematocrit.	30 days
Secondary	Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding	Bleeding will be classified by the TIMI hemorrhage classification; Severity: Major: Intracranial hemorrhage; A =5 g/dL decrease in the hemoglobin concentration; A =15% absolute decrease in the hematocrit; Minor: Observed blood loss: A = 3 g/dL decrease in the hemoglobin concentration; A = 10% absolute decrease in the hematocrit; No observed blood loss: A = 4 g/dL decrease in the hemoglobin concentration; A = 12% absolute decrease in the hematocrit; Minimal: • Any clinically overt sign of hemorrhage (including imaging) that is associated with a < 3 g/dL decrease in hemoglobin concentration or < 9% decrease in the hematocrit.	3 years
Secondary	Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding	Bleeding will be classified by the TIMI hemorrhage classification; Severity: Major: Intracranial hemorrhage; A =5 g/dL decrease in the hemoglobin concentration; A =15% absolute decrease in the hematocrit; Minor: Observed blood loss: A = 3 g/dL decrease in the hemoglobin concentration; A = 10% absolute decrease in the hematocrit; No observed blood loss: A = 4 g/dL decrease in the hemoglobin concentration; A = 12% absolute decrease in the hematocrit; Minimal: • Any clinically overt sign of hemorrhage (including imaging) that is associated with a < 3 g/dL decrease in hemoglobin concentration or < 9% decrease in the hematocrit.	4 years
Secondary	Number of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding	Bleeding will be classified by the TIMI hemorrhage classification; Severity: Major: Intracranial hemorrhage; A =5 g/dL decrease in the hemoglobin concentration; A =15% absolute decrease in the hematocrit; Minor: Observed blood loss: A = 3 g/dL decrease in the hemoglobin concentration; A = 10% absolute decrease in the hematocrit; No observed blood loss: A = 4 g/dL decrease in the hemoglobin concentration; A = 12% absolute decrease in the hematocrit; Minimal: • Any clinically overt sign of hemorrhage (including imaging) that is associated with a < 3 g/dL decrease in hemoglobin concentration or < 9% decrease in the hematocrit.	5 years
Secondary	Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding	Type 0: No bleeding Type 1: Bleeding that is not actionable&does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: Any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.; Type 3 Type 3a; Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL; Any transfusion with overt bleeding Type 3b; Overt bleeding plus hemoglobin drop =5 g/dL*; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring intravenous vasoactive agents Type 3c; Intracranial hemorrhage; Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: Fatal bleeding	30 days
Secondary	Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding	Type 0: no bleeding Type 1: bleeding that is not actionable&does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.; Type 3 Type 3a; Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL; Any transfusion with overt bleeding Type 3b; Overt bleeding plus hemoglobin drop =5 g/dL*; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring intravenous vasoactive agents Type 3c; Intracranial hemorrhage; Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding	3 years
Secondary	Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding	Type 0: no bleeding Type 1: bleeding that is not actionable&does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.; Type 3 Type 3a; Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL; Any transfusion with overt bleeding Type 3b; Overt bleeding plus hemoglobin drop =5 g/dL*; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring intravenous vasoactive agents Type 3c; Intracranial hemorrhage; Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding	4 years
Secondary	Number of Participants With Bleeding Academic Research Consortium (BARC) Bleeding	Type 0: no bleeding Type 1: bleeding that is not actionable&does not cause the patient to seek unscheduled performance of studies,hospitalization,or treatment by a healthcare professional Type 2: any overt, actionable sign of hemorrhage that does not fit the criteria for type 3,4,or 5 but does meet at least 1 of the following criteria:requiring nonsurgical, medical intervention by a healthcare professional; leading to hospitalization or increased level of care; prompting evaluation.; Type 3 Type 3a; Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL; Any transfusion with overt bleeding Type 3b; Overt bleeding plus hemoglobin drop =5 g/dL*; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring intravenous vasoactive agents Type 3c; Intracranial hemorrhage; Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision Type 4: CABG-related bleeding Type 5: fatal bleeding	5 years
Secondary	Number of Participants With Major Adverse Events (MAE)	death; myocardial infarction; stroke; Transfusion of =2 units of blood; TIMI major or minor bleeding; major arrhythmia; unplanned coronary revascularization for ischemia; any unplanned surgery or therapeutic radiologic procedure; renal failure; sternal wound dehiscence; infection requiring antibiotics for treatment; intubation for > 48 hours; post-pericardiotomy syndrome	30 days
Secondary	Number of Participants With Complete Revascularization (Residual = 0)	Complete anatomic revascularization requires revascularization of all vessels =2.0 mm reference vessel diameter with a DS =60% (both as measured by core angiographic laboratory analysis).; -While this will be the pre-specified criteria for anatomically significant lesions, sensitivity analysis will be performed using different criteria (e.g. =2.5 mm vessels, DS =70%, etc.); From the baseline angiogram, the angiographic core lab will identify and designate those lesions and vessels requiring revascularization in all subjects according to this definition, prior to knowledge of the extent of actual revascularization.; Following PCI, the angiographic core lab will determine the extent of revascularization (vessels with TIMI 2or3 flow post procedure with a core laboratory DS <50% considered successfully revascularized).; Following CABG, the angiographic core lab will determine the extent of revascularization or if there is a repeat angiogram during the index hospitalization.	At Baseline
Secondary	Number of Participants With Definite Stent Thrombosis (ST) or Symptomatic Graft Occlusion	- Definite ST occurred by either angiographic/pathologic confirmation of ST.; Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&presence of at least 1 of the following criteria within 48-hours: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive &occlusive thrombus; Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.; -Symptomatic graft occlusion: Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	In-hospital (= 7 days of post index procedure)
Secondary	Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion	- Definite ST occurred by either angiographic/pathologic confirmation of ST.; Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&presence of at least 1 of the following criteria within 48-hours: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive &occlusive thrombus; Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.; -Symptomatic graft occlusion: Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	1 year
Secondary	Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion	- Definite ST occurred by either angiographic/pathologic confirmation of ST.; Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&presence of at least 1 of the following criteria within 48-hours: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive &occlusive thrombus; Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.; -Symptomatic graft occlusion: Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	2 years
Secondary	Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion	- Definite ST occurred by either angiographic/pathologic confirmation of ST.; Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&presence of at least 1 of the following criteria within 48-hours: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive &occlusive thrombus; Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.; -Symptomatic graft occlusion: Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	3 years
Secondary	Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion	- Definite ST occurred by either angiographic/pathologic confirmation of ST.; Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&presence of at least 1 of the following criteria within 48-hours: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive &occlusive thrombus; Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.; -Symptomatic graft occlusion: Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	4 years
Secondary	Number of Participants With Definite Stent Thrombosis or Symptomatic Graft Occlusion	- Definite ST occurred by either angiographic/pathologic confirmation of ST.; Angiographic confirmation:The presence of a thrombus that originates in the stent/in the segment 5mm proximal/distal to the stent&presence of at least 1 of the following criteria within 48-hours: Acute onset of ischemic symptoms at rest; New ischemic ECG changes; Typical rise&fall in cardiac biomarkers; Non-occlusive &occlusive thrombus; Pathological confirmation:Evidence of recent thrombus within the stent determined at autopsy/via examination of tissue retrieved following thrombectomy.; -Symptomatic graft occlusion: Ischemic symptoms in the presence of =50% diameter stenosis in a coronary bypass graft.	5 years